Corient Private Wealth LP Invests $13.69 Million in Insulet Corporation $PODD

Corient Private Wealth LP bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, Holdings Channel.com reports. The firm bought 89,892 shares of the medical instruments supplier’s stock, valued at approximately $13,686,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Insulet in the second quarter worth approximately $1,018,582,000. State Street Corp grew its position in shares of Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after acquiring an additional 65,317 shares during the period. Geode Capital Management LLC increased its stake in shares of Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares in the last quarter. Invesco Ltd. increased its stake in shares of Insulet by 10.5% in the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after purchasing an additional 141,167 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the period.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.36% of the company’s stock.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Insulet Trading Up 1.2%

Shares of PODD stock opened at $145.13 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The stock has a fifty day simple moving average of $154.46 and a two-hundred day simple moving average of $181.15. The firm has a market capitalization of $10.06 billion, a PE ratio of 27.13, a PEG ratio of 1.14 and a beta of 1.10. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same period in the previous year, the business earned $1.17 earnings per share. The business’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, analysts predict that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Citigroup lifted their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Benchmark decreased their price objective on Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Robert W. Baird set a $175.00 price objective on Insulet in a research report on Thursday, August 6th. UBS Group cut their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Finally, Barclays reduced their target price on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.